Should I buy or sell Anebulo Pharmaceuticals stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Anebulo Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ANEB shares. View ANEB analyst ratings or view top-rated stocks .

What is Anebulo Pharmaceuticals' stock price target for 2024?

3 brokerages have issued 12 month price targets for Anebulo Pharmaceuticals' shares. Their ANEB share price targets range from $6.00 to $8.00. On average, they predict the company's stock price to reach $6.67 in the next twelve months. This suggests a possible upside of 182.5% from the stock's current price. View analysts price targets for ANEB or view top-rated stocks among Wall Street analysts .

How have ANEB shares performed in 2023?

Anebulo Pharmaceuticals' stock was trading at $2.4237 at the beginning of the year. Since then, ANEB stock has decreased by 2.6% and is now trading at $2.36. View the best growth stocks for 2023 here .

Are investors shorting Anebulo Pharmaceuticals?

Anebulo Pharmaceuticals saw a decline in short interest in November. As of November 15th, there was short interest totaling 2,500 shares, a decline of 56.1% from the October 31st total of 5,700 shares. Based on an average trading volume of 18,700 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.1% of the shares of the stock are sold short. View Anebulo Pharmaceuticals' Short Interest .

When is Anebulo Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, February 9th 2024. View our ANEB earnings forecast .

How were Anebulo Pharmaceuticals' earnings last quarter?

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) released its quarterly earnings results on Wednesday, September, 20th. The company reported ($0.10) EPS for the quarter, meeting analysts' consensus estimates of ($0.10).

When did Anebulo Pharmaceuticals IPO?

(ANEB) raised $21 million in an IPO on Friday, May 7th 2021. The company issued 3,000,000 shares at a price of $6.00-$8.00 per share. The Benchmark Company acted as the underwriter for the IPO.

Who are Anebulo Pharmaceuticals' major shareholders?

Anebulo Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Tower Research Capital LLC TRC (0.08%). View institutional ownership trends .

How do I buy shares of Anebulo Pharmaceuticals?

Shares of ANEB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Anebulo Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ANEB)

$2.36

-0.01 (-0.42%)

(As of 12/4/2023 ET)

Compare

Today's Range: $2.11
▼
$2.44
50-Day Range: $1.71
▼
$3.27
52-Week Range: $1.62
▼
$4.05

Volume: 5,750 shs
Average Volume: 9,514 shs
Market Capitalization: $60.49 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.67

Anebulo Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 182.5% Upside
$6.67 Price Target
Short Interest: Healthy
0.11% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.29
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.46) to ($0.47) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

379th out of 952 stocks

Pharmaceutical Preparations Industry

169th out of 434 stocks

3.5

Analyst's Opinion

Consensus Rating
Anebulo Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.67, Anebulo Pharmaceuticals has a forecasted upside of 182.5% from its current price of $2.36.
Amount of Analyst Coverage
Anebulo Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.11% of the float of Anebulo Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Anebulo Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Anebulo Pharmaceuticals has recently decreased by 56.14%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Anebulo Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Anebulo Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ANEB.

2.9

News and Social Media Coverage

News Sentiment
Anebulo Pharmaceuticals has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Anebulo Pharmaceuticals this week, compared to 0 articles on an average week.
MarketBeat Follows
Only 1 people have added Anebulo Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Anebulo Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
85.90% of the stock of Anebulo Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 27.44% of the stock of Anebulo Pharmaceuticals is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Anebulo Pharmaceuticals are expected to decrease in the coming year, from ($0.46) to ($0.47) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Anebulo Pharmaceuticals is -5.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Anebulo Pharmaceuticals is -5.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Anebulo Pharmaceuticals has a P/B Ratio of 5.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Anebulo Pharmaceuticals Stock (NASDAQ:ANEB)

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

ANEB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ANEB Stock News Headlines

November 29, 2023 | americanbankingnews.com

Short Interest in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Declines By 56.1%

November 21, 2023 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: 60 Degrees Pharmaceuticals, Inc. (SXTP) and Brainsway (BWAY)

December 5, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 17, 2023 | markets.businessinsider.com

Buy Recommendation for Anebulo Pharmaceuticals: Promising Financial Outlook and Potential Breakthrough in Acute Cannabis Intoxication Treatment

November 15, 2023 | msn.com

Anebulo Pharmaceuticals GAAP EPS of -$0.10 beats by $0.02

November 14, 2023 | finance.yahoo.com

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates

November 6, 2023 | finance.yahoo.com

Here's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

October 19, 2023 | msn.com

Are Medical Stocks Lagging Anebulo Pharmaceuticals (ANEB) This Year?

December 5, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

October 11, 2023 | benzinga.com

Director at Anebulo Pharmaceuticals Acquires Company Stock Options Worth 26,097 Shares

October 6, 2023 | marketwatch.com

Anebulo Pharmaceuticals Names Richie Cunningham as CEO

October 6, 2023 | finance.yahoo.com

Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors

October 6, 2023 | finance.yahoo.com

Anebulo Pharmaceuticals Announces New CEO

September 25, 2023 | msn.com

HC Wainwright & Co. Reiterates Anebulo Pharmaceuticals (ANEB) Buy Recommendation

September 25, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Its Buy Rating for Anebulo Pharmaceuticals (ANEB)

September 23, 2023 | nasdaq.com

Maxim Group Initiates Coverage of Anebulo Pharmaceuticals (ANEB) with Buy Recommendation

September 22, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA), Aurinia Pharmaceuticals (AUPH) and Aquestive Therapeutics (AQST)

September 20, 2023 | finance.yahoo.com

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates

September 18, 2023 | msn.com

HC Wainwright & Co. Initiates Coverage of Anebulo Pharmaceuticals (ANEB) with Buy Recommendation

September 18, 2023 | markets.businessinsider.com

Substance Use Disorder Focused Anebulo Could Be Attractive Acquisition Target, Analyst Says

September 18, 2023 | markets.businessinsider.com

Anebulo Pharmaceuticals (ANEB) Has a New Rating from H.C. Wainwright

August 30, 2023 | finance.yahoo.com

Anebulo Pharmaceuticals to Present at Upcoming Investor and Scientific Conferences

August 22, 2023 | finance.yahoo.com

Anebulo (ANEB) Gains on Positive FDA Response for ANEB-001

August 21, 2023 | markets.businessinsider.com

Anebulo Pharma: FDA Provides Favorable Input On Studies To Support ANEB-001 Approval

August 21, 2023 | finance.yahoo.com

Anebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 Extension

May 30, 2023 | finance.yahoo.com

We Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Needs To Drive Business Growth Carefully

May 19, 2023 | finance.yahoo.com

Down -26.43% in 4 Weeks, Here's Why You Should You Buy the Dip in Anebulo Pharmaceuticals, Inc. (ANEB)

See More Headlines

Receive ANEB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anebulo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 9/20/2023
Today: 12/04/2023
Next Earnings (Estimated): 2/09/2024
Fiscal Year End: 6/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ANEB
CUSIP: N/A
CIK: 1815974
Web: www.anebulo.com
Phone: 512-598-0931
Fax: N/A
Employees: 2
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $6.67
High Stock Price Target: $8.00
Low Stock Price Target: $6.00
Potential Upside/Downside: +182.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.46)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-11,730,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -97.93%
Return on Assets: -89.18%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 12.62
Quick Ratio: 12.62

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.41 per share
Price / Book: 5.76

Miscellaneous

Outstanding Shares: 25,630,000
Free Float: 3,614,000
Market Cap: $60.49 million
Optionable: Not Optionable
Beta: -1.14

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Dr. Joseph F. Lawler M.D. (Age 51)
Ph.D., Founder & Chairman
Comp: $11k
Dr. Kenneth C. Cundy Ph.D. (Age 64)
Chief Scientific Officer
Comp: $425.15k
Mr. Richard Anthony Cunningham (Age 52)
CEO & Director
Mr. Daniel V. George (Age 53)
Principal Accounting Officer, Acting CFO & Secretary
Mr. Scott L. Anderson
Head of Investor Relations & Public Affairs

Key Competitors

View All Competitors

Institutional Ownership

Tower Research Capital LLC TRC
Bought 14,750 shares on 11/14/2023
Ownership: 0.081%

View All Institutional Transactions

ANEB Stock Analysis - Frequently Asked Questions

Should I buy or sell Anebulo Pharmaceuticals stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Anebulo Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ANEB shares.
View ANEB analyst ratings or view top-rated stocks.
What is Anebulo Pharmaceuticals' stock price target for 2024?: 3 brokerages have issued 12 month price targets for Anebulo Pharmaceuticals' shares. Their ANEB share price targets range from $6.00 to $8.00. On average, they predict the company's stock price to reach $6.67 in the next twelve months. This suggests a possible upside of 182.5% from the stock's current price.
View analysts price targets for ANEB or view top-rated stocks among Wall Street analysts.
How have ANEB shares performed in 2023?: Anebulo Pharmaceuticals' stock was trading at $2.4237 at the beginning of the year. Since then, ANEB stock has decreased by 2.6% and is now trading at $2.36.
View the best growth stocks for 2023 here.
Are investors shorting Anebulo Pharmaceuticals?: Anebulo Pharmaceuticals saw a decline in short interest in November. As of November 15th, there was short interest totaling 2,500 shares, a decline of 56.1% from the October 31st total of 5,700 shares. Based on an average trading volume of 18,700 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.1% of the shares of the stock are sold short.
View Anebulo Pharmaceuticals' Short Interest.
When is Anebulo Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, February 9th 2024.
View our ANEB earnings forecast.

How were Anebulo Pharmaceuticals' earnings last quarter?: Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) released its quarterly earnings results on Wednesday, September, 20th. The company reported ($0.10) EPS for the quarter, meeting analysts' consensus estimates of ($0.10).
When did Anebulo Pharmaceuticals IPO?: (ANEB) raised $21 million in an IPO on Friday, May 7th 2021. The company issued 3,000,000 shares at a price of $6.00-$8.00 per share. The Benchmark Company acted as the underwriter for the IPO.
Who are Anebulo Pharmaceuticals' major shareholders?: Anebulo Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Tower Research Capital LLC TRC (0.08%).
View institutional ownership trends.
How do I buy shares of Anebulo Pharmaceuticals?: Shares of ANEB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ANEB) was last updated on 12/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial